nach oben

Erschienen in:

01.06.2019 | News item

Serious AEs linked with investigational faecal microbiota

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Use of faecal microbiota for transplantation (FMT) is potentially linked with serious adverse events (AEs) due to transmission of multi-drug resistant organisms (MDROs), warns the US FDA. …

IND = Investigational New Drug application

US Food and Drug Administration. Fecal Microbiota for Transplantation: Safety Communication- Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms. Internet Document : 18 Jun 2019. Available from: URL: https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/fecal-microbiota-transplantation-safety-communication-risk-serious-adverse-reactions-due

Titel: Serious AEs linked with investigational faecal microbiota
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63893-8

Argatroban/heparin

Case report

Meropenem/tigecycline interaction

Case report

Warfarin

Case report

Ciclosporin

Case report

Cardiovascular AEs more common with carfilzomib than bortezomib

Clinical study

Pneumococcal-vaccine

Case report

Springer Medizin

Serious AEs linked with investigational faecal microbiota

Excerpt

Weitere Artikel der Ausgabe 1/2019

Argatroban/heparin

Meropenem/tigecycline interaction

Warfarin

Ciclosporin

Cardiovascular AEs more common with carfilzomib than bortezomib

Pneumococcal-vaccine

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Argatroban/heparin

Meropenem/tigecycline interaction

Warfarin

Ciclosporin

Cardiovascular AEs more common with carfilzomib than bortezomib

Pneumococcal-vaccine